MacroGenics | MGNX - Net Income


MacroGenics reported $-14.16M in Net Income for its fiscal quarter ending in December of 2025.





Net Income Change Date
AbbVie USD 695M 1.12B Mar/2026
Amgen USD 1.82B 486M Mar/2026
AstraZeneca USD 3.08B 754M Mar/2026
Biogen USD 319.5M 368.4M Mar/2026
Bristol-Myers Squibb USD 2.68B 1.59B Mar/2026
Daiichi Sankyo JPY 86.63B 41.32B Dec/2025
Eli Lilly USD 7.4B 760M Mar/2026
Genmab DKK 31M 370M Dec/2025
Geron USD -3.64M 27.5M Mar/2026
Gilead Sciences USD 2.02B 162M Mar/2026
J&J USD 5.24B 119M Mar/2026
Karyopharm Therapeutics USD -102.2M 71.42M Dec/2025
MacroGenics USD -14.16M 30.98M Dec/2025
Merck USD -4.24B 7.2B Mar/2026
Pfizer USD 2.69B 4.34B Mar/2026
Puma Biotechnology USD 20.32M 24.85M Sep/2024
Regeneron Pharmaceuticals USD 727.2M 117.4M Mar/2026
Roche Holding CHF 5.47B 1.76B Dec/2025
Xencor USD -128.92M 122.26M Mar/2026